Expression And Its Clinical Significance Of AMACR And PSCA In Prostate Cancer

Objective: To explore the relationship between the expression of AMACR and PSCA and the tumor grading and clinical staging, By detectingα-methyl-acyl-coenzyme A racemase (AMACR) and prostate stem cell antigen (PSCA) in prostate cancer and benign prostatic hyperplasia tissues, To study the value of its clinical diagnosis and prognosis of PCa.Methods: Select 25 patients with prostate cancer and 30 patients whith benign prostatic hyperplasia who recerved treatment in The Cancer Hospital Of Guangxi Medical University from August 2005 to December 2009. Without preoperative radiotherapy or chemotherapy before operation. All of the specimens were fixed in formalin, embedded in paraffin. The immunohistochemistry was used to detect the expression of AMACR and PSCA.χ~2 test and pearson correlations was performed by using SPSS16.0.Results: The expression of AMACR showed a significant difference between the prostate cancer (80%,20/25)and benign prostatic hyperplasia (0%,0/30)(P<0.05). The expression of PSCA showed no significant difference between the prostate cancer(100%,25/25) and benign prostatic hyperplasia( 83.3%,25/30).But the rate of strong expression between these were significant difference. Pca 64%(16/25), BPH33.3%(10/30)(P<0.05). The expression of PSCA and clinical stage has a clear correlation(P<0.05).Conclusion:(1)The high expression of AMACR in the tissue of prostate cancer clue to they can be used as tumor marker which has high sensitivity rate and specificity rate for diagnosis of prostate cancer.(2)The rate of strong expression of PSCA in the prostate cancer is higher than that of prostatic hyperplasia and PSCA expression in prostate cancer and clinical stage have significant correlation ,which clue to prostate cancer dignosis and prognosis.(3)Combining the expression of AMACR and PSCA may significantly improve the diagnostic sensitivity.